Randomized Trial of Pharmacist-Led Antimicrobial Stewardship for Pneumonia

An 18-month prospective randomized controlled trial from April 2023 to October 2024 at a tertiary care hospital. The dataset contains results from 700 adult patients with hospital-acquired or ventilator-associated pneumonia, comparing pharmacist-led stewardship to standard care. It was authored by Nawal Alsubaie and shared under a CC-BY-4.0 license.

Use Cases

• Analyze the relationship between pharmacist-led intervention and the primary outcome of appropriate_antimicrobial_prescription_on_day_three using odds ratios.
• Model the reduction in hospital_length_of_stay and total_antimicrobial_treatment_duration based on treatment group assignment.
• Compare clinical_cure_rates and antimicrobial-related_adverse_event frequencies between intervention and control groups.
• Assess the impact of multidisciplinary_communication_training and therapeutic_drug_monitoring on prescription appropriateness.

Strengths

• Data from a randomized controlled trial design with 700 patient records (366 intervention, 334 control).
• Results include statistically significant odds ratios and confidence intervals for key outcomes like prescription appropriateness (OR=2.26).
• Trial conducted over a defined 18-month period, providing clear temporal coverage.

Limitations

• Data is presented in a PDF report; specific row-level patient data or column definitions are not provided as a structured table.
• Findings are from a single tertiary care hospital, limiting geographic generalizability.
• The 2.3 MB file size indicates a summary document, not a large-scale raw dataset for machine learning.

Provenance

Source

figshare, authored by Nawal Alsubaie.

Collection Method

Prospective randomized controlled trial.

Time Range

April 2023 to October 2024.

Freshness

null

Geography

A single tertiary care hospital (location unspecified).